All In Biotech

Drug Trial Radar · NCT01270971

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Last checked: Nov 19, 2026Latest source record: Feb 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

594

Actual

Start

Dec 1, 2010

Primary completion

Nov 30, 2012

Study completion Jan 8, 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.

Conditions

  • Onychomycosis of Toenails

Interventions

  • AN2690 Topical Solution, 5%Drug

    AN2690 Topical Solution, 5%, applied once daily for 48 weeks

  • Solution VehicleDrug

    AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52Time frame: Week 52

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site

    Tucson, Arizona

  • Investigational Site

    Hot Springs, Arkansas

  • Investigational Site

    Burbank, California

  • Investigational Site

    Los Angeles, California

  • Investigational Site

    San Francisco, California

  • Investigational Site

    Denver, Colorado

  • Investigational Site

    Orange Park, Florida

  • Investigational Site

    Boise, Idaho

  • Investigational Site

    Evansville, Indiana

  • Investigational Site

    Overland Park, Kansas

  • Investigational Site

    Baltimore, Maryland

  • Investigational Site

    Fridley, Minnesota

  • Investigational Site

    Omaha, Nebraska

  • Investigational Site

    New York, New York

  • Investigational Site

    New York, New York

  • Investigational Site

    Rochester, New York

  • Investigational Site

    Winston-Salem, North Carolina

  • Investigational Site

    Cincinnati, Ohio

  • Investigational Site

    South Euclid, Ohio

  • Investigational Site

    Portland, Oregon

  • Investigational Site

    Providence, Rhode Island

  • Investigational Site

    Germantown, Tennessee

  • Investigational Site

    Austin, Texas

  • Investigational Site

    College Station, Texas

  • Investigational Site

    San Antonio, Texas

  • Investigational Site

    Lynchburg, Virginia

  • Investigational Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.